New pill targets rare bile duct cancer mutation in late-stage trial
NCT ID NCT05987358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and neither they nor their doctors know which they receive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Lanzhou University Second Hospital
Lanzhou, Gansu, 730030, China
-
Tangshan People's Hospital
Tangshan, Hebei, 063001, China
-
Third Affiliated Hospital of Naval Medical University
Shanghai, Shanghai Municipality, 200433, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300181, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.